Want to see NZ:RUA full AI Analyst Report?
Top Page
Rua Bioscience Ltd.
(RUA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.03
Action:N/A
Date:10/05/26
The score is primarily held down by weak financial performance, driven by persistent large losses and ongoing cash burn despite improving revenue. Technicals also add pressure, with the price below key moving averages and negative MACD indicating a weak trend. Valuation contributes only modestly because the negative P/E reflects losses and there is no dividend yield support.
Positive Factors
Strong Revenue Growth
Rapid customer and total revenue growth shows expanding commercial traction across Rua’s medicinal cannabis markets. If sustained, this larger revenue base can improve operating leverage, support broader product investment, and strengthen the company’s ability to scale international distribution.
Negative Factors
Persistent Unprofitable Operations
Rua’s revenue growth has not yet translated into a sustainable earnings model. Deeply negative net margins and a negative gross margin indicate that current scale, pricing, or cost structure remains inadequate, leaving profitability dependent on substantial operational improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid customer and total revenue growth shows expanding commercial traction across Rua’s medicinal cannabis markets. If sustained, this larger revenue base can improve operating leverage, support broader product investment, and strengthen the company’s ability to scale international distribution.
Read all positive factors
Rua Bioscience Ltd. (RUA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.22M
Dividend YieldN/A
Average Volume (3M)66.44K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth70.82%
EPS Growth41.04%
CountryNZ
Employees15
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding452,588,930
10 Day Avg. Volume119,367
30 Day Avg. Volume66,435
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.21
Price to Sales (P/S)3.64
P/FCF Ratio-3.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rua Bioscience Ltd. Business Overview & Revenue Model
Company Description
Rua Bioscience Limited, a company founded in 2016 and headquartered in Gisborne, New Zealand, is dedicated to the investigation, refinement, and production of medicinal products for both the New Zealand market and international distribution. Their...
Rua Bioscience Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
20
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.58M | 1.90M | 85.84K | 357.68K | 24.23K |
| Gross Profit | -1.26M | 923.23K | -118.31K | 18.12K | -5.22M |
| EBITDA | -2.96M | -2.92M | -13.30M | -5.25M | -6.63M |
| Net Income | -3.36M | -3.46M | -13.72M | -5.96M | -8.64M |
Balance Sheet | |||||
| Total Assets | 7.17M | 6.77M | 7.74M | 20.95M | 33.57M |
| Cash, Cash Equivalents and Short-Term Investments | 533.70K | 241.42K | 895.13K | 4.56M | 9.94M |
| Total Debt | 1.76M | 735.60K | 147.78K | 114.58K | 824.00K |
| Total Liabilities | 2.92M | 1.88M | 973.13K | 830.31K | 9.38M |
| Stockholders Equity | 4.25M | 4.89M | 6.77M | 20.12M | 24.20M |
Cash Flow | |||||
| Free Cash Flow | -3.02M | -2.72M | -3.60M | -5.80M | -7.18M |
| Operating Cash Flow | -3.02M | -2.72M | -3.60M | -5.73M | -6.78M |
| Investing Cash Flow | -302.00 | 105.76K | 2.21M | 6.67M | 5.59M |
| Financing Cash Flow | 3.31M | 1.95M | -94.78K | -120.38K | -208.64K |
Rua Bioscience Ltd. Technical Analysis
Negative
―
Price Trends
0.03
Negative
0.03
Negative
0.03
Negative
Market Momentum
>-0.01
Positive
38.42
Neutral
93.58
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:RUA, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 0.03, equal to the 50-day MA of 0.03, and equal to the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.42 is Neutral, neither overbought nor oversold. The STOCH value of 93.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:RUA.
Rua Bioscience Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $45.49M | 16.07 | ― | 3.60% | 17.86% | 20.79% | |
63 Neutral | $34.15M | 0.03 | ― | ― | 29.55% | -11.97% | |
60 Neutral | $35.82M | 54.00 | ― | ― | 16.01% | -28.57% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $458.30M | 30.91 | 14.07% | 0.67% | 22.44% | 23.14% | |
44 Neutral | $12.22M | -2.70 | ― | ― | 70.82% | 41.04% |
* General Sector Average
NZ:RUA
Rua Bioscience Ltd.
0.03
>-0.01
-24.32%
NZ:AFT
AFT Pharmaceuticals Ltd.
4.33
1.52
54.20%
NZ:BLT
BLIS Technologies Limited
0.03
0.01
68.75%
NZ:VTL
Vital Limited
―
―
―
NZ:PHL
Promisia Healthcare Limited
0.65
0.22
50.00%
NZ:TAH
Third Age Health Services Limited
4.46
0.03
0.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.